Medicare Enrolled
Dr. Kenneth Desrosier, M.D.
Rheumatology · San Antonio, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Desrosier from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Desrosier?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Desrosier
Dr. Kenneth Desrosier is a rheumatology specialist in San Antonio, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Desrosier performed 110,877 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Desrosier received a total of $15,047 from 38 pharmaceutical and/or device companies across 811 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Desrosier is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 14% volume in TX
$15,047 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗110,877
Medicare services
Top 14% in TX for rheumatology
Not available
Unique patients (not deduplicated)
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
70,000 | $4 | $10 |
| Romosozumab injection (Evenity) for osteoporosis | 23,520 | $8 | $20 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
8,400 | $33 | $75 |
| Denosumab injection (Prolia/Xgeva) | 4,800 | $19 | $45 |
| Joint lubricant injection (Durolane) An injection of hyaluronan or its derivative, specifically Durolane, administered directly into a joint space. |
1,680 | $5 | $16 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
737 | $90 | $188 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
655 | $11 | $25 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
291 | $59 | $133 |
| Injection, methylprednisolone acetate, 40 mg | 155 | $6 | $25 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
132 | $47 | $298 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
101 | $133 | $265 |
| Ultrasound-guided large joint aspiration or injection This procedure uses ultrasound imaging to guide the removal of fluid from or the injection of medication into a large joint. |
81 | $91 | $202 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
70 | $47 | $148 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
64 | $22 | $150 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
62 | $99 | $300 |
| Telephone medical discussion, 5-10 minutes A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters. |
51 | $27 | $82 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
32 | $130 | $272 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
22 | $49 | $133 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
13 | $87 | $186 |
| Chronic care management, first 20 min/month This service covers the first 20 minutes of clinical staff time directed by a healthcare professional each calendar month to manage chronic conditions. |
11 | $49 | $65 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
7.8% high complexity
91.1% medium
1.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$15,047
Total received (2018-2024)
Avg $2,150/year across 7 years
Top 24% in TX for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
38
Companies
811
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,098
2023
$4,111
2022
$2,984
2021
$2,106
2020
$402
2019
$191
2018
$2,155
Payments by company (2024)
Amgen Inc.
$514
UCB, Inc.
$497
Janssen Biotech, Inc.
$363
Novartis Pharmaceuticals Corporation
$332
ABBVIE INC.
$272
Lilly USA, LLC
$204
PFIZER INC.
$180
Aurinia Pharma U.S., Inc.
$133
Fresenius Kabi USA, LLC
$116
AstraZeneca Pharmaceuticals LP
$110
E.R. Squibb & Sons, L.L.C.
$98
Organon Llc
$77
Boehringer Ingelheim Pharmaceuticals, Inc.
$44
ANI Pharmaceuticals, Inc.
$42
Octapharma USA, Inc.
$40
GlaxoSmithKline, LLC.
$29
Alexion Pharmaceuticals, Inc.
$29
Fidia Pharma USA Inc.
$19
Top 3 companies account for 44.3% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$2,119
UCB, Inc.
$2,009
Janssen Biotech, Inc.
$1,431
Novartis Pharmaceuticals Corporation
$1,157
AbbVie Inc.
$1,133
PFIZER INC.
$829
Horizon Therapeutics plc
$665
ABBVIE INC.
$652
Lilly USA, LLC
$624
GlaxoSmithKline, LLC.
$587
E.R. Squibb & Sons, L.L.C.
$472
AstraZeneca Pharmaceuticals LP
$469
Horizon Pharma plc
$353
Genentech USA, Inc.
$352
McKesson Specialty Care Distribution, LLC
$328
GENZYME CORPORATION
$206
AbbVie, Inc.
$184
Fresenius Kabi USA, LLC
$163
Aurinia Pharma U.S., Inc.
$162
Octapharma USA, Inc.
$140
Organon LLC
$138
Pacira Therapeutics, Inc.
$116
Boehringer Ingelheim Pharmaceuticals, Inc.
$100
Mallinckrodt LLC
$88
Antares Pharma, Inc.
$83
Organon Llc
$77
Alexion Pharmaceuticals, Inc.
$75
ANI Pharmaceuticals, Inc.
$69
Flexion Therapeutics, Inc.
$61
Ferring Pharmaceuticals Inc.
$41
Fidia Pharma USA Inc.
$35
Cumberland Pharmaceuticals, Inc.
$28
MEDAC PHARMA, INC.
$22
NeuroMetrix Inc
$20
GRT US Holding, Inc.
$18
Ultragenyx Pharmaceutical Inc.
$15
Daiichi Sankyo Inc.
$15
FIDIA PHARMA USA INC.
$11
Top 3 companies account for 36.9% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · Actemra · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · EUFLEXXA · EVENITY · EVUSHELD · Enbrel · HADLIMA · HUMIRA · HYMOVIS · Humira · Hymovis · IDACIO · INFLECTRA · KEVZARA · KRYSTEXXA · LUPKYNIS · Morphabond ER · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · Otezla · Otrexup · PURIFIED CORTROPHIN GEL · Prolia · Qutenza · RAYOS · REDITREX · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · TALTZ · TAVNEOS · TREMFYA · Tyenne · XELJANZ · Zilretta
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Rheumatologists in nearby ZIP areas
51
County median income
$70,571
Nearest hospital to ZIP centroid (approximate)
BAPTIST NEIGHBORHOOD HOSPITAL THOUSAND OAKS
4.8 mi
4.8 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Desrosier is a mixed practice specialist, with above-average Medicare volume (top 14% in TX), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Desrosier experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Desrosier performed 70,000 certolizumab injection (cimzia) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Desrosier receive payments from pharmaceutical companies?
Yes. Dr. Desrosier received a total of $15,047 from 38 companies across 811 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Desrosier's costs compare to other rheumatologists in San Antonio?
Dr. Desrosier's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Desrosier) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in San Antonio
Browse rheumatologists in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in TX
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in TX
Which TX rheumatologists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
UCB, Inc. Payments to Doctors
See all physicians who received payments from UCB, Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology